ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult (MDC), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology.
